These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 6039768)
1. Clinical evaluation of a new alkylating agent, azetepa, in one hundred and twenty-five cases of malignant tumors. Choy DS; Arandia J; Rosenbaum I Int J Cancer; 1967 Mar; 2(2):189-93. PubMed ID: 6039768 [No Abstract] [Full Text] [Related]
2. [Anticancer chemotherapy with evaluation of combined treatments]. Saito T Poumon Coeur; 1968; 24(1):129-31. PubMed ID: 5652199 [No Abstract] [Full Text] [Related]
3. Intra-articular use of cytostatica. (Thio-Tepa, Azetepa and Osmium acid). Langkilde M; Rossel I Acta Rheumatol Scand; 1967; 13(2):92-100. PubMed ID: 4961259 [No Abstract] [Full Text] [Related]
4. Azetepa--a new alkylating agent. McLean JA Isr J Med Sci; 1965 Jul; 1(4):805-7. PubMed ID: 5323047 [No Abstract] [Full Text] [Related]
5. Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163). Wampler GL; Kuperminc M; Regelson W Cancer Chemother Pharmacol; 1980; 4(1):49-52. PubMed ID: 7363402 [TBL] [Abstract][Full Text] [Related]
6. Effects of meturedepa (NSC-51325) in 233 patients with advanced cancer. Eastern Clinical Drug Evaluation Program. Moore GE; Bross ID; Ausman R; Nadler S; Jones R; Slack N; Rimm AA Cancer Chemother Rep; 1968 Oct; 52(6):667-73. PubMed ID: 4895430 [No Abstract] [Full Text] [Related]
7. AZETEPA (NSC-64826) IN STAGE IV BREAST CANCER. FALKSON G; FALKSON HC Cancer Chemother Rep; 1964 Dec; 43():19-24. PubMed ID: 14250646 [No Abstract] [Full Text] [Related]
8. [Chemotherapy of cancer]. Saito T Gan No Rinsho; 1968 Jan; 14(1):71-3. PubMed ID: 5692170 [No Abstract] [Full Text] [Related]
9. [Chromosome aberrations induced by fortrin in human lymphocytes in cultures and in vivo]. Sinkus AG; Sinkuvene DS Tsitologiia; 1976 Sep; 18(9):1115-9. PubMed ID: 1014102 [TBL] [Abstract][Full Text] [Related]
10. Clinical experience with a new anticancer agent, carbazilquinone (NSC-134679). Saito T; Oira S; Wakui A; Yokoyama M; Takahashi H Cancer Chemother Rep; 1973; 57(4):447-57. PubMed ID: 4586952 [No Abstract] [Full Text] [Related]
11. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma. McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666 [No Abstract] [Full Text] [Related]
12. Clinical experience with a new alkylating agent, azetepa, in a variety of solid tumors. CHOY DS; STYLIANOU S Cancer Chemother Rep; 1962 Oct; 23():47-50. PubMed ID: 14021063 [No Abstract] [Full Text] [Related]
14. [Results of the clinical study of a preparation of diiodobenzotef in malignant tumors]. Karev NI; Garin AM; Blokhina NG; Pershin MP; Trapeznikova MF Klin Med (Mosk); 1975 May; 52(5):50-3. PubMed ID: 1133992 [No Abstract] [Full Text] [Related]
15. Response of human tumours 'in vitro' to CB-1954 (5-aziridinyl-2, 4-dinitrobenzamide). Bhat AV; Rao KV; Bapat CV Indian J Cancer; 1977 Jun; 14(2):132-5. PubMed ID: 914303 [No Abstract] [Full Text] [Related]
16. Phase II evaluation of diaziquone in gastric and pancreatic cancers. A Southeastern Cancer Study Group Trial. DeSimone P; Kramer B; Omura GA; Bartolucci AA Am J Clin Oncol; 1986 Oct; 9(5):401-2. PubMed ID: 3776902 [TBL] [Abstract][Full Text] [Related]
17. [Chronic leukemia therapy with trenimon]. Rattka P Pol Tyg Lek; 1965 Dec; 20(49):1857-8. PubMed ID: 5867901 [No Abstract] [Full Text] [Related]
18. [Chemotherapy of malignant tumors. 44]. Seidenglanz G Pharm Prax; 1970; 6():122-38. PubMed ID: 4917035 [No Abstract] [Full Text] [Related]